Therefore, mitotic drivers, such as MPS1 or Aurora B inhibitors that foster segregation errors, and, indirectly, subsequent micronuclei‐driven inflammation seem interesting alternatives to be combined with BH3 mimetics and immune checkpoint blockade for more effective anti‐cancer therapy. Here, AURKB is linked to cancer.